C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Review, H1 2016

  • ID: 3766757
  • Report
  • Region: Global
  • 45 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • ChemoCentryx, Inc.
  • MORE
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Review, H1 2016

Summary

The report ‘C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Review, H1 2016’, provides in depth analysis on C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4)
- The report reviews C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • ChemoCentryx, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) Overview

Therapeutics Development

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Products under Development by Stage of Development

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Products under Development by Therapy Area

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Products under Development by Indication

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Products Glance

Late Stage Products

Early Stage Products

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Products under Development by Companies

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development

AstraZeneca Plc

ChemoCentryx, Inc.

Globavir Biosciences, Inc.

Kyowa Hakko Kirin Co., Ltd.

Ono Pharmaceutical Co., Ltd.

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Drug Profiles

AZD-2098 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-6239 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-0001163 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBV-3019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mogamulizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Dormant Projects

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Discontinued Products

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Featured News & Press Releases

Jul 29, 2015: Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.

Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab

Dec 10, 2014: Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab in Advanced Solid Tumors

Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study

Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab

Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab

Feb 10, 2014: Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab

Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma

Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab

Dec 13, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase III Trial Of Mogamulizumab In Patients With Cutaneous T-Cell Lymphoma In US

Dec 11, 2012: Kyowa Hakko Kirin Announces Presentation Of Phase II Clinical Trial Results Of Mogamulizumab At ASH Annual Meeting

Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe

Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab

May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan

Mar 30, 2012: Kyowa Hakko Kirin Receives New Drug Application Approval For POTELIGEO Injection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by ChemoCentryx, Inc., H1 2016

Pipeline by Globavir Biosciences, Inc., H1 2016

Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016

Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AstraZeneca Plc
  • ChemoCentryx, Inc.
  • MORE
The recently published report 'C-C Chemokine Receptor Type 4 - Pipeline Review, H1 2016'; C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Furthermore, C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.

The report 'C-C Chemokine Receptor Type 4 - Pipeline Review, H1 2016' outlays comprehensive information on the C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 4 and 2 respectively.

Note: Product cover images may vary from those shown
5 of 6
AstraZeneca Plc
ChemoCentryx, Inc.
Globavir Biosciences, Inc.
Kyowa Hakko Kirin Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll